猪嗝铁铁
Lv6
1990 积分
2022-04-01 加入
-
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
4个月前
已完结
-
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
6个月前
已完结
-
Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma – The Oregon Health and Science University Experience
6个月前
已完结
-
Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis
6个月前
已完结
-
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study
6个月前
已完结
-
Final analysis of the CLL2-GIVe trial (obinutuzumab, ibrutinib, and venetoclax) in untreated CLL with del(17p)/TP53mut
6个月前
已完结
-
Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?
6个月前
已完结
-
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
9个月前
已完结
-
Cytokine Storm Syndrome
9个月前
已完结
-
Cytokine Storm Drugs Move from CAR T to COVID-19
10个月前
已关闭